CD19 and lymphoma: An example of such an IHC analysis is depicted for a CAR-T cell study, where immunocompromised NSG mice, a mouse strain based on NOD/SCID with complete null mutation of the interleukin 2 receptor (IL2r) γ chain [25,26], bearing a CD19-positive lymphoma were treated with CAR-T cells co-expressing the reporter protein DTPA-R.